GSK Pumps In $1 Billion To Raise Equity In Indian Pharma Subsidiary
This article was originally published in PharmAsia News
Executive Summary
GSK said it will infuse $1 billion to purchase shares and raise its stake in its Indian arm to 75%, the highest limit allowed in India. Brushing aside the growth setback in the last few months, the British firm reaffirmed a long view of the Indian health care market.
You may also be interested in...
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket
Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.